A side-by-side comparison of two Healthcare investors: New Enterprise Associates (Power Score 80/100) and Perceptive Advisors (Power Score 82/100), both ranked among the most active firms tracked in this category.
| New Enterprise Associates | Perceptive Advisors | |
|---|---|---|
| Power Score™ | 80/100 | 82/100 |
| Assets Managed | $25B+ | Approximately $11B (across its strategies as of 30 June 2026, per the firm's own About page; the firm's Form ADV Item 5.F figure could not be read) |
| Founded | 1977 | 1999 |
| Headquarters | Menlo Park, CA | New York, NY |
| Sectors | Technology, Healthcare, Life Sciences | Biotech, Life Sciences, Medical Devices, Diagnostics, Digital Health, Healthcare IT |
NEA was founded in 1977 by three men who each brought a different piece of the puzzle: Dick Kramlich, who had trained under legendary investor Arthur Rock; Frank Bonsal, an investment banker who had taken startups public; and Chuck Newhall, who had managed investment funds at T. Rowe Price. Deliberately built with offices on both coasts from day one - unusual for the era - NEA's first fund raised just $16 million, a fraction of the more than $25 billion it manages today.
View full New Enterprise Associates profile →Perceptive Advisors is a life sciences investment manager registered with the SEC as an investment adviser (CRD 154703, SEC registration effective 4 October 2010). It says it runs four strategies. The Perceptive Life Sciences Fund invests globally in public and private companies developing biotechnology products, drugs, medical devices and diagnostics, with the majority of investments in publicly traded small and mid cap companies, and participates in growth rounds, crossover rounds, IPOs and public follow-ons. Credit Opportunities, launched with its first closed-end fund in 2014, lends to healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health, life sciences research and healthcare IT, and states a range of $20M to $300M per investment and approximately $3.5B of capital raised for private credit. Capital Solutions provides structured capital to later-stage and commercial-stage life sciences companies. The venture strategy, run through the Perceptive Xontogeny Venture Funds, invests primarily at seed and Series A in biotechnology, medtech, healthtech, digital health and healthcare tools and services, states investments of $10M to $50M when leading or co-leading a Series A, states over $700M across its venture funds, and says its people take board seats. The firm describes its team as scientists, technologists, molecular biologists, MDs and PhDs.
View full Perceptive Advisors profile →